Parkinson's disease is a degenerative disease affecting the central nervous system. While there's no cure for it, there are drugs available to help treat it. The following report takes a closer look at the global Parkinson's disease drug market and where it's headed.
- Advertising -
Parkinson's disease is a debilitating condition involving the gradual degradation of the central nervous system. As you may know, the central nervous system is responsible for the movements of our bodies.
Therefore, people who suffer from Parkinson's disease often struggle to perform otherwise common movements, such as grabbing and holding a cup.
Some people assume that Parkinson's disease is a relatively uncommon or even rare condition, but this isn't necessarily true.
- Advertising -
According to the Global Burden of Disease (GBD), over 6 million people are currently living with Parkinson's disease. It typically affects older adults aged 60 and over, but even young adults can develop this central nervous system disorder.
And once the initial symptoms of Parkinson's disease begins to manifest, it generally becomes progressively worse.
Even though there's no cure for Parkinson's disease, there are drugs available to slow its progression and suppress some of its symptoms. MAO-B inhibitors, for example, are antidepressant drugs that suppress the central nervous system to slow down the progression of Parkinson's disease.
Dopamine agonists may also be used to treat Parkinson's disease. Neither MAO-B inhibitors nor dopamine agonists will cure Parkinson's disease, but they can reduce the symptoms associated with this common disease.
Unbeknownst to many people, there's a special day of the year that's intended to raise awareness for Parkinson's disease. Known as World Parkinson's Day, it's held on April 11 each year, and on this day, millions of people from throughout the world shine the spotlight on this degenerative and debilitating disease.
The Parkinsons Disease Drug Market Insights 2019, Global and Chinese Analysis and Forecast to 2024 report by ReportsnReports is a comprehensive study of the global Parkinson's disease drug market. Featuring 135 professionally written pages, it's one of the largest studies on the Parkinson's disease drug market.
Whether you work in the market or invest in the market, you should check out this report to gain a deeper understanding of the current and future state of the Parkinson's disease drug market.
Within this report, you'll find statistics and forecasts for the Parkinson's disease drug market. This report segments the global Parkinson's disease drug market by several criteria.
On the basis of product type, the market is segmented into Carbidopa/Levodopa, Dopamine Receptor Agonists and MAO-Inhibitors. On the basis of end-user application, the market is segmented into hospital, online and retail pharmacies.
On the basis of key vendors, the market is segmented into Teva, Novartis AG, GSK, AbbVie, Merck and Boehringer Ingelheim.